U.S. pharma big copyright scrapped two experimental weight loss capsules previous year—a when-daily tablet, lotiglipron, as a result of elevated liver enzymes in addition to a 2 times-each day pill, danuglipron, as a result of strong Unwanted side effects—but CEO Albert Bourla has reported the company is set to “Engage in and earn” while in